# Acute Chest Syndrome

Acute chest syndrome requires immediate imaging, oxygenation assessment, empiric treatment for pulmonary infection, lung-expansion measures, and early transfusion escalation when hypoxemia or radiographic disease progresses.

**Clinical question:** How should physicians identify, stabilize, investigate, and escalate treatment for acute chest syndrome in sickle cell disease?

Updated: 2026-08-24T18:12:49.361989+00:00

## What matters in practice
- Treat a new pulmonary infiltrate plus fever or respiratory symptoms in sickle cell disease as acute chest syndrome because deterioration to hypoxemic respiratory failure can be rapid. [10][11][12][13]
- Obtain chest radiography, pulse oximetry or arterial blood gas testing, CBC with differential, chemistry testing, and blood group and screen at initial evaluation; add microbiologic testing when clinically indicated. [11][13]
- Use supplemental oxygen, judicious hydration, analgesia that avoids excessive sedation, empiric antibiotics, and lung-expansion measures while monitoring closely for worsening respiratory failure. [3][10][14][16]
- Escalate toward transfusion support for worsening anemia with respiratory symptoms or progressive respiratory disease; partial exchange transfusion is described for deterioration despite only mild anemia with hemoglobin greater than 9 g/dL. [3][4]
- After recovery, discuss hydroxyurea to reduce recurrent acute chest syndrome; hydroxyurea and chronic transfusion therapy have reduced recurrence in children and adults. [2][3]

## Identify acute chest syndrome and triage respiratory risk

Do not wait for a fully evolved pulmonary syndrome before initiating treatment.

Diagnose acute chest syndrome (ACS) when a patient with sickle cell disease has a new pulmonary infiltrate involving at least one lung segment, excluding atelectasis, plus at least one compatible feature: chest pain, fever above 38.5°C, tachypnea, wheeze, or cough. The clinical-radiographic construct overlaps with pneumonia; therefore, obtain chest imaging in every patient with sickle cell disease who presents with respiratory symptoms. [10][13]

Treat new or increasing oxygen requirement, respiratory distress, hypoxemia, hypercapnia, extensive or progressive infiltrates, or declining clinical status as escalation signals. ACS can rapidly evolve into acute hypoxemic respiratory failure, multiorgan failure, and death; it is a leading cause of death in sickle cell disease. [12][13][16]

Recognize differing dominant patterns by age and context. Children more often have fever, cough, wheeze, and increased work of breathing in infectious presentations, whereas adults may present with chest pain, dyspnea, extremity pain, or concurrent vaso-occlusive disease. ACS may develop during hospitalization for pain, after surgery, or after marrow infarction with fat embolism. [3][10][13]
- Place patients with hypoxemia, rising work of breathing, altered mental status, or rapidly progressive infiltrates in a monitored setting with immediate access to transfusion and advanced respiratory support. [10][12][16]
- Avoid attributing chest symptoms solely to vaso-occlusive pain: hypoventilation related to chest pain and opioid exposure can promote hypoxia and pulmonary sickling. [16]
- Consider pulmonary embolism or infarction, infection, pulmonary fat embolism, and rib infarction as precipitating or coexisting causes rather than mutually exclusive alternatives. [10][12][14]

*Clinical patterns that change the immediate diagnostic and escalation pathway. [3][10][12][13][16]*

| Pattern | Clues | Immediate implication |
| --- | --- | --- |
| Infectious-predominant ACS | Fever, cough, wheeze, increased work of breathing; particularly common in children. [3][13] | Obtain indicated cultures and respiratory viral testing, then initiate empiric antibiotics while supporting oxygenation. [11][14] |
| Pain-associated hypoventilation | Concurrent vaso-occlusive pain, chest pain, or opioid exposure with evolving hypoxia. [16] | Provide effective but carefully monitored analgesia, avoid excessive sedation, and use lung-expansion measures. [10][16] |
| Progressive respiratory ACS | Worsening hypoxemia, hypercapnia, respiratory acidosis, or increasing infiltrates. [4][5][12] | Escalate respiratory support and urgently coordinate transfusion strategy with hematology and critical care. [3][4][5] |
| Fat embolic or infarct-associated ACS | ACS after bone marrow infarction, severe vaso-occlusive disease, or postoperative stress. [10][12][16] | Treat as potentially rapidly progressive ACS; do not defer respiratory support or transfusion assessment while establishing the precipitant. [12][16] |

## Obtain imaging, oxygenation data, and transfusion-ready laboratory testing

The initial evaluation should establish ACS, define respiratory severity, and prepare for transfusion if deterioration occurs.

Obtain chest radiography, CBC with differential, oxygen-saturation assessment or arterial blood gas testing, standard chemistry testing, and blood group and screen in suspected ACS. A chest radiograph remains the reference imaging study for identifying the requisite new infiltrate, but an initially unrevealing film should not override an evolving clinical syndrome. [11][14]

Use arterial blood gas testing when oxygenation or ventilation is uncertain or worsening. A PaO2 below 60 mm Hg is a reported hypoxemia marker in ACS; rising carbon dioxide or respiratory acidosis supports escalation to noninvasive or invasive ventilatory support. [4][14]

Order blood cultures, sputum bacterial cultures, nasopharyngeal or sputum viral testing, and other infection-directed studies when presentation and local epidemiology warrant them. These tests should refine etiologic management but should not delay empiric treatment for ACS. [11][14]

Lung ultrasound is a useful point-of-care adjunct when a rapid bedside assessment is needed. In a meta-analysis of six studies involving 625 patients, 97% aged 21 years or younger, pooled sensitivity was 0.92 and specificity was 0.89; applicability to adults remains less certain. [12]
- Trend oxygen saturation and respiratory examination rather than relying on a single assessment because ACS can progress after presentation or during admission for vaso-occlusive pain. [3][11][16]
- Reassess chest imaging when respiratory findings worsen or clinical severity and the initial radiograph are discordant. [11][13]
- Review baseline pulmonary disease, prior ACS frequency and severity, recent pulmonary complications, pregnancy, and operative exposure because these factors may increase perioperative ACS risk or identify patients needing heightened surveillance. [10]

*Initial diagnostic studies and how they guide immediate management. [10][11][12][14]*

| Study | Decision use | Interpretation or limitation |
| --- | --- | --- |
| Chest radiograph | Confirm a new pulmonary infiltrate and establish an imaging baseline for progression. [10][11][14] | Required diagnostic imaging in the standard definition; radiographic findings may lag early clinical disease. [10][13] |
| Pulse oximetry and arterial blood gas | Determine oxygen requirement and identify ventilatory failure requiring escalation. [11][14] | PaO2 below 60 mm Hg is reported hypoxemia; hypercapnia with respiratory acidosis supports noninvasive ventilation consideration. [4][14] |
| CBC with differential and chemistry testing | Define anemia, leukocyte pattern, and metabolic complications while preparing for transfusion decisions. [11] | Interpret hemoglobin in relation to respiratory trajectory, not as an isolated transfusion trigger. [3][4] |
| Type and screen | Avoid delay if simple or exchange transfusion becomes necessary. [11] | Obtain during initial ACS evaluation rather than after respiratory decompensation. [11] |
| Lung ultrasound | Rapid bedside assessment when radiography is delayed or serial evaluation is useful. [12] | Pooled performance is strongest in pediatric populations; adult generalizability remains uncertain. [12] |

## Start supportive treatment and empiric antimicrobial therapy in parallel

Management is directed at interrupting hypoxemia, atelectasis, infection, and pain-related hypoventilation.

Administer supplemental oxygen for impaired gas exchange and titrate respiratory support to clinical severity. Noninvasive support such as CPAP may be used when oxygenation worsens, while intubation and invasive mechanical ventilation are indicated when respiratory dysfunction cannot be supported noninvasively. [10] In pediatric critical-care practice, worsening hypoxia and hypercapnia with respiratory acidosis are common triggers for noninvasive ventilation. [4][5]

Use hydration cautiously rather than aggressively. ACS management includes modest or judicious fluid administration, because excess fluid can worsen pulmonary gas exchange in an acute lung injury syndrome. [3][14][16] Provide analgesia promptly enough to permit deep breathing and coughing, but monitor closely for excessive opioid sedation and hypoventilation. [14][16]

Initiate empiric antibiotics because infection is a frequent precipitant and ACS is clinically difficult to distinguish from pneumonia. Macrolide antibiotics are included in pediatric ACS management recommendations; obtain indicated cultures before antibiotics when feasible without delaying therapy. [3][11][14]

Use incentive spirometry and consider chest physiotherapy as lung-expansion measures, particularly in pain-associated hypoventilation or hospitalized vaso-occlusive episodes. Bronchodilators may be useful when wheeze or obstructive airway disease is present; routine use for every patient is not established by the cited evidence. [4][10]
- Escalate to high-flow oxygen, CPAP, BiPAP, or invasive ventilation according to oxygenation, ventilation, and work of breathing rather than waiting for a single fixed saturation threshold. [4][5][10]
- Use noninvasive ventilation only where monitoring and staff familiarity are available; pediatric survey data show it is commonly used in experienced centers, but prospective outcome data remain limited. [5]
- Corticosteroids remain a selective, uncertain intervention: potential benefit has been reported, but safety, efficacy, and optimal dosing require further prospective study. [3]

*Supportive interventions and escalation triggers in acute chest syndrome. [3][4][5][10][14][16]*

| Intervention | Use | Escalate or modify when |
| --- | --- | --- |
| Supplemental oxygen | Provide for impaired gas exchange and titrate to clinical response. [10][14] | Increasing requirement or persistent hypoxemia should prompt higher-level respiratory support and transfusion assessment. [10][12] |
| Analgesia | Treat pain promptly to reduce splinting and hypoventilation. [14][16] | Reduce sedating burden and reassess ventilation if somnolence, hypoventilation, or hypercapnia emerges. [16] |
| Judicious fluids | Use modest hydration as part of ACS care. [3][14][16] | Avoid fluid excess when pulmonary findings or oxygenation worsen. [3][16] |
| Empiric antibiotics | Begin during ACS treatment because infection is a frequent precipitant and pneumonia overlap is substantial. [3][11][14] | Refine therapy when microbiologic testing or clinical course identifies an alternative cause. [11] |
| Incentive spirometry or chest physiotherapy | Promote lung expansion, especially with pain-related hypoventilation. [10][16] | Increase surveillance if pulmonary symptoms or infiltrates develop despite use. [11][16] |

## Use respiratory trajectory and anemia pattern to choose transfusion support

Transfusion decisions should be made early with hematology when ACS is worsening.

Consider simple transfusion when worsening anemia accompanies respiratory symptoms. This approach is used to improve oxygen-carrying capacity and reduce the proportion of circulating sickled erythrocytes, but the patient’s respiratory trajectory is more important than hemoglobin alone. [3][4]

Consider partial exchange transfusion when respiratory status deteriorates despite only mild anemia, specifically when hemoglobin is greater than 9 g/dL in the cited pediatric treatment approach. This avoids excessive post-transfusion hemoglobin increase while reducing sickle hemoglobin exposure in progressive disease. [3]

Involve critical care and hematology urgently for worsening hypoxemia, hypercapnia, respiratory acidosis, escalating noninvasive support, or need for invasive ventilation. Severe ACS has historically been managed with transfusion or exchange transfusion, although prospective comparative trials of these strategies are lacking. [4][5]
- Have blood compatibility testing available at presentation because transfusion may be required rapidly as respiratory disease progresses. [11]
- Do not use a restrictive ICU transfusion framework intended for general critical illness as a substitute for ACS-specific transfusion assessment; ACS treatment decisions integrate oxygenation, pulmonary progression, and baseline anemia. [3][4][23]
- Monitor clinical work of breathing, oxygenation, carbon dioxide retention when measured, and radiographic progression after transfusion or respiratory-support escalation. [4][10][11]

### When to move beyond ward-level care

Transfer or manage in a higher-acuity setting when respiratory failure is evolving: worsening hypoxia is a common noninvasive ventilation trigger, and hypercapnia causing respiratory acidosis is an additional trigger. CPAP, BiPAP, high-flow oxygen, and invasive ventilation should be selected according to gas-exchange failure and local capability. [4][5][10]
- Progressive infiltrates plus worsening oxygenation should trigger concurrent critical-care and transfusion planning rather than sequential consultations. [11][12]
- Mechanical ventilation is indicated when the degree of respiratory dysfunction cannot be managed with oxygen and noninvasive support. [10]

*Transfusion and respiratory-support escalation framework. [3][4][5][10][11]*

| Clinical situation | Next action | Rationale |
| --- | --- | --- |
| Worsening anemia with respiratory symptoms | Assess for simple transfusion with hematology involvement. [4] | Simple transfusion is commonly used for ACS with anemia and respiratory compromise. [3][4] |
| Hemoglobin greater than 9 g/dL with deteriorating respiratory status | Consider partial exchange transfusion. [3] | This strategy is described when respiratory deterioration occurs despite mild anemia. [3] |
| Worsening hypoxia | Escalate oxygen delivery and consider noninvasive ventilation in a monitored setting. [4][5][10] | Worsening hypoxia is a commonly used NIV indication in pediatric practice. [4] |
| Hypercapnia with respiratory acidosis or failure of noninvasive support | Escalate critical-care management and evaluate for invasive ventilation. [4][10] | Ventilatory failure requires support beyond supplemental oxygen alone. [4][10] |

## Address precipitants and reduce recurrence after recovery

ACS often has more than one precipitant; prevention should follow the pattern of the index event.

Evaluate for infection, pulmonary fat embolism after marrow infarction, pulmonary infarction, perioperative stress, and pain-related hypoventilation. These mechanisms may coexist and should guide targeted testing and prevention rather than delay syndrome-directed management. [3][10][12][16]

After recovery, discuss hydroxyurea for recurrent ACS prevention. Hydroxyurea has reduced recurrent ACS episodes in children and adults, and chronic transfusion therapy has also been used to prevent recurrence in selected patients. [2][3]

For patients anticipating surgery, identify prior ACS, chronic lung disease, recent clustering of pulmonary complications, pregnancy, increasing age, and procedural invasiveness as features associated with greater perioperative pulmonary risk. Obtain a recent chest radiograph for baseline comparison when postoperative imaging may be needed, and assess for obstructive or restrictive lung disease when clinical history suggests it. [10]
- Document the index ACS phenotype: infectious symptoms, concurrent vaso-occlusive pain, postoperative onset, severity of hypoxemia, need for transfusion, and respiratory-support level. These data guide subsequent prevention planning. [3][10][16]
- Discuss hydroxyurea after an ACS recovery rather than limiting disease-modifying therapy discussions to recurrent pain alone. [2][3]
- Use individualized transfusion planning for patients with recurrent severe ACS or anticipated high-risk procedures in conjunction with the sickle cell team. [2][10][22]

*Post-ACS prevention decisions. [2][3][10][22]*

| Risk context | Preventive action | Clinical purpose |
| --- | --- | --- |
| Prior ACS after recovery | Discuss hydroxyurea. [2][3] | Hydroxyurea has demonstrated reduction in recurrent ACS episodes. [2][3] |
| Recurrent ACS or selected high-risk disease | Consider chronic transfusion strategy with sickle cell specialists. [2] | Chronic transfusion therapy has been used to prevent recurrent ACS. [2] |
| Upcoming surgery | Review ACS history, pulmonary comorbidity, recent pulmonary events, pregnancy status, and procedure invasiveness; obtain baseline chest imaging when useful. [10][22] | Perioperative optimization can reduce risk of ACS-related complications. [10][22] |

## Common questions

### Can lung ultrasound replace chest radiography for acute chest syndrome?

Lung ultrasound can accelerate bedside assessment and had pooled sensitivity of 0.92 and specificity of 0.89 in a predominantly pediatric meta-analysis, but the standard diagnostic definition remains based on a new chest-imaging infiltrate and adult generalizability is uncertain. [10][12]

### When should exchange transfusion be considered in acute chest syndrome?

Consider partial exchange transfusion when respiratory status is deteriorating despite only mild anemia, described in children with hemoglobin greater than 9 g/dL; involve hematology early because comparative prospective evidence is limited. [3][5]

## References
1. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000001029
2. Standard management of sickle cell disease complications ☆ : Hematology/Oncology and Stem Cell Therapy — journals.lww.com — https://journals.lww.com/hosct/fulltext/2020/13020/standard_management_of_sickle_cell_disease.8.aspx
3. How I treat acute chest syndrome in children with sickle cell disease - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0006497120450736
4. A Survey of the Management of Acute Chest Syndrome in Children with Sickle Cell Disease in Centres in UK and Western Europe - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0006497119729930
5. Therapeutic approach to pediatric patients with acute chest syndrome: national multicenter survey of non invasive ventilation (NIV) and transfusion - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0929693X21001172
6. Guidelines for the management of emergencies and critical ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2110582025000688
7. Prevention and Management of Acute Chest Syndrome ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/ejh.70166
8. Incentive spirometry to prevent acute chest syndrome in ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/ajh.25805
9. Acute chest syndrome: sickle cell disease - Paul - 2011 — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2011.01647.x
10. Essentials of Pulmonology — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7173444
11. Sickle Cell Disease and Acute Chest Syndrome: Epidemiology, Diagnosis, Management, Outcomes — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7120070
12. Diagnostic Test Accuracy of Lung Ultrasound for Acute Chest Syndrome in Sickle Cell Disease: A Systematic Review and Meta-analysis - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10258441
13. Acute Chest Syndrome - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK441872
14. Acute Chest Syndrome — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10332774
15. Acute Respiratory Distress Syndrome - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK436002
16. Sickle Cell Crisis - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK526064
17. Complications of Sickle Cell Disease and Current Management Approaches - Addressing Sickle Cell Disease - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK566466
18. Evidence-based management of pregnant women with sickle ... — ashpublications.org — https://ashpublications.org/hematology/article/2022/1/408/493563/Evidence-based-management-of-pregnant-women-with
19. Emerging concepts in sickle cell disease acute chest syndrome — ashpublications.org — https://ashpublications.org/bloodrci/article/2/2/100060/566434/Emerging-concepts-in-sickle-cell-disease-acute
20. Optimizing Pulmonary Health in Children With Sickle Cell ... — publications.aap.org — https://publications.aap.org/pediatricsinreview/article/46/11/633/205351/Breathing-Easier-Optimizing-Pulmonary-Health-in
21. American Society of Hematology 2020 guidelines for sickle ... — ashpublications.org — https://ashpublications.org/bloodadvances/article/4/8/1554/454384/American-Society-of-Hematology-2020-guidelines-for
22. Optimizing management of sickle cell disease in patients ... — ashpublications.org — https://ashpublications.org/hematology/article/2021/1/405/482957/Optimizing-management-of-sickle-cell-disease-in
23. Red Blood Cell Transfusion in the ICU | Critical Care - American College of Chest Physicians — www.chestnet.org — http://www.chestnet.org/guidelines-and-topic-collections/guidelines/critical-care/red-blood-cell-transfusion-in-the-icu
24. NATIONAL INSTITUTE FOR HEALTH AND CLINICAL ... — www.nice.org.uk — https://www.nice.org.uk/guidance/cg143/evidence/appendices-cd-scope-and-how-this-guideline-was-developed-pdf-186634336

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.